Nonspecific orbital inflammation and thyroid eye disease, a rare comorbidity: report of two cases and review of literature

Bahram Eshraghi 1, Amin Dehghan 2, Niloofar Javadi 2 and Mohammadreza Fazel 1*

Abstract

Background: To present the very rare comorbidity of developing non-specific orbital inflammation (NSOI) in two patients with histories of definite thyroid eye disease (TED).

Case presentation: Both patients complained of new-onset progressive proptosis although their thyroid disease was controlled and computed tomography scan revealed an intrabulbar inflammatory mass. The pathological assessment indicated that both patients had developed fibrosing NSOI. Therefore, intravenous corticosteroids were administered. The mass regressed and the amount of proptosis was decreased in both patients.

Conclusions: We reviewed all related cases in the literature and extracted their clinical and radiological characteristics for this paper. Ophthalmologists should consider TED and NSOI in patients with a new-onset complaint of proptosis. Despite rare comorbidity of TED and NSOI, it should be considered especially in patients with refractory proptosis, and lead to its further evaluation and prompt management.

Keywords: Non-specific orbital inflammation, thyroid eye disease, comorbidity, orbital mass, prednisolone

Background

Thyroid eye disease (TED) is an autoimmune orbital inflammatory disorder associated with thyroid inflammatory diseases. Sight-threatening TED occurs in 3-7% of cases due to optic nerve compression or corneal exposure, but the majority of the cases are mild and self-limiting. The most common ocular sign of TED is upper eyelid retraction, occurring in 90% of the patients, followed by proptosis and ocular motility restriction. Shan et al. reported that deposition of hyaluronan (a hydrophilic glycosaminoglycan) between extraocular muscle fibers as the main histopathologic findings in TED, which may cause proptosis and ocular motility restriction. Besides, infiltration of inflammatory cells and their cytokines are responsible for soft tissue enlargement. Since the orbital walls consist of several rigid bones, the events mentioned causing increased intraorbital pressure [1]. Orbital imaging, particularly computed tomography scan (CT-Scan) and magnetic resonance imaging (MRI), may be necessary to confirm the diagnosis. Treatment strategy includes medical interventions to normalize the thyroid function tests and suppress orbital inflammation in the active phase of the disease. Surgical procedures are performed only under specific conditions [2, 3].

Idiopathic orbital inflammatory disease, also known as non-specific orbital inflammation (NSOI), is a benign, non-infectious inflammatory orbital disorder that is not associated with any systemic or local etiologies. This disease accounts for about 8% to 10% of orbital masses, proving it to be one of the most common causes of proptosis in adults. NSOI may have various presentations, such as inflammation of the lacrimal gland in its most common form-known as dacryoadenitis, myositis of one or more extraocular muscles (EOMs), and some
other rare presentations [4]. There are rare case reports of concomitant occurrence of an NSOI presentation with TED [5–10].

In the present study, we report two cases presenting with simultaneous NSOI and TED in their clinical courses. In addition, we review previous investigations that reported comorbidity of TED and any form of NSOI.

Case presentation

Case 1

A 50-year-old man with a history of hyperthyroidism and smoking presented to our clinic with bilateral proptosis for the past year. He received a single-dose iodine therapy after Graves’ disease was diagnosed for him 10 years ago, and he had been on anti-thyroid medication (methimazole) ever since. He was otherwise healthy.

The best corrected visual acuity (BCVA) was 20/20, and the relative afferent pupillary defect (RAPD) was + positive in the left eye (OS). He had developed 2 mm superior eyelid retraction OS, with a clinical activity score (CAS) of 0 out of 7 on both sides. The degree of proptosis measured by the Hertel exophthalmometer was 26 mm and 27 mm in his right eye (OD) and OS, respectively. Ocular motility was mildly restricted in superior gazes on both sides. Anterior segment examination, color vision, intraocular pressure (IOP) and dilated fundus examination were all within normal limits in both eyes. A generalized depression visual field defect was detected in his left side.

CT-Scan revealed an intraorbital infiltrative mass that expanded to intraconal and extraconal spaces with no EOM enlargement (Fig. 1A). MRI with gadolinium-based contrast agents revealed a hyper-intense infiltrative lesion in T1-weighted with fat suppression images (Fig. 1B). Based on the clinical findings, the patient underwent surgical procedures for medial and inferior wall orbital decompression OD and biopsy of the orbital mass OS in one session. Pathological assessments confirmed the diagnosis of simultaneous TED and chronic fibrosing NSOI, so 1 gr intravenous methylprednisolone per day was administered for three consecutive days.

Further rheumatologic investigations revealed normal antibody profile. Examination of the patient five-month post-operative revealed resolution of the orbital mass as well as a normal visual field.

One month later, the patient underwent decompression surgery in the inferior wall OD and medial wall OS to manage the remained proptosis. After the second surgery, the patient was visited at regular intervals for four years, and Hertel exophthalmometer revealed proptosis of 21.5 mm in both eyes with no ocular motility restriction bilaterally. No mass was observed in CT-scan (Fig. 1C).

Case 2

A 23-year-old woman was referred to the oculoplastic clinic of Feiz Eye Hospital, Isfahan, Iran with the chief complaint of gradual progressive proptosis that had started in her left eye a year before the visit. Despite being euthyroid, the anti-TPO antibody was positive in the patient’s laboratory tests and she had a history of thyroid inflammation during the previous four years. She did not take any anti-thyroid medications, and the smoking history was negative.

BCVA was 20/20 and RAPD was negative bilaterally. Furthermore, she had 1 mm superior eyelid retraction OD and 3 mm superior eyelid retraction OS, and CAS of 0 out of 7 bilaterally. The degree of proptosis measured by the Hertel exophthalmometer was 20 mm OD and 22 mm OS. Anterior and posterior segments did not have remarkable findings and IOP was normal in both
eyes. CT-scan findings were also unremarkable. Based on the clinical findings, we decided to perform a medial wall decompression OS to resolve the proptosis.

The amount of proptosis was not significantly reduced during the 6-month postoperative visits, and severe ocular motility restriction and pain were also detected in all superior directions OS. The previous CT-scan was re-examined, and a small infratemporal infiltrative mass was detected (Fig. 1D). A new CT-scan was performed to evaluate the condition and it revealed the enlargement of the previously undiagnosed lesion (Fig. 1E). Based on the clinical and radiologic findings, the diagnosis of NSOI associated with TED was highly suspected, and the patient underwent orbital biopsy. The pathological assessment revealed that the orbital mass was a fibrous NSOI, confirming our clinical diagnosis, and further rheumatologic assessments were normal. To suppress the inflammation, 500 mg intravenous methylprednisolone was administered for 3 consecutive days and the mass was completely resolved (Fig. 1F). The patient was followed for two years when she developed a mass in the left sub-brow area extending to the forehead. The pathology report of the surgical biopsy sample confirmed chronic NSOI. Oral methylprednisolone 1 mg/kg was administered and gradually tapered over three months. In addition, mycophenolate mofetil 500 mg every 12 h was also administered for four months. The proptosis was not increased and her clinical condition remained stable.

Discussion

Described for the first time in 1905, NSOI refers to orbital inflammation without any specific local or systemic underlying pathologies. It is diagnosed if other similar conditions are ruled out including TED, orbital lymphoproliferative diseases, and other systemic inflammations involving the orbit [11, 12].

Both of the cases presented in this report had a definite diagnosis of TED, and NSOI was subsequently diagnosed for them following new clinical manifestations. TED and NSOI can occur in the same patient at different times. For example, Kubota et al. reported a patient with a history of Grave’s ophthalmopathy presenting with an upper eyelid mass, for which pathological and serological assessments revealed the diagnosis of IgG4-related ocular disorder [7].

To date, only six patients with simultaneous NSOI and TED have been reported in the literature [7–10]. This comorbidity can occur in any thyroid function status, for example, hyperthyroidism as seen in our first patient. The second reported case here was euthyroid with positive anti-TPO antibodies before the new-onset left proptosis. Hyperthyroidism, hypothyroidism, and euthyroidism have been observed in six [5, 7, 8, 10], two [5], and one [5] previously reported patients, respectively. However, the thyroid status was not determined in patients reported by Detorakis et al. and Shieh et al. [6, 9].

According to review of the literature, comorbidity of NSOI and TED occurs almost equally among men and women with a ratio of 6:5. The median age of the previously reported patients was 47, ranging between 22 and 68 years [5–10]. Both our cases presented with the chief complaint of a new-onset proptosis. As described in Table 1, proptosis was reported in all but two of the previous patients [7, 10]. For example, Tachibana et al. described a patient presenting with severe ocular motility restriction and pain without proptosis. Their radiologic assessment revealed the superior rectus muscle enlargement, which led to the diagnosis of TED associated with myositis [7].

Patients with orbital involvement and a history of any thyroid inflammation are highly suspected of TED. In addition, certain clinical manifestations and specific radiological findings may help differentiate TED from other orbital lesions [2, 3]. Upper eyelid retraction, which is the most frequent sign in patients with TED [2], was detected in both our cases. This finding is not usually observed in NSOI. When extraocular muscles are involved, tendons are usually spared in TED but not in NSOI [2, 11, 12]. The presence of orbital masses are highly associated with NSOI or other orbital malignancies but not with TED [4, 11–13].

Shen et al. reported three hyperthyroid patients with CT-scan reports of extraocular muscle enlargement, tendon sparing and intraorbital inflammatory masses, which resulted in the diagnosis of simultaneous TED and NSOI [9].

Corticosteroids are the first-line treatment for the active phase of NSOI and TED [2, 4]. Except for the sclerosing form, other types of NSOI dramatically respond to intravenous or oral steroids, and some researchers believe that the response rate to corticosteroids is a promising way to differentiate between TED and NSOI [11, 12]. The molecular mechanism of action in corticosteroid therapy in these patients is not completely known yet. Future molecular studies should address how corticosteroids therapy resolves orbital inflammatory masses, possibly through RNA-Seq experiments, like the studies on the genes involved in retinal dystrophies and retinitis pigmentosa [14–16]. As in the previous reports, we tried corticosteroids as the first line treatment to manage our patients. The diagnosis of fibrosing NSOI associated with TED was confirmed in both our patients. As expected, the orbital inflammatory masses were resolved in both cases.

New clinical manifestations in patients with controlled thyroid status and TED suggests the need for new
| Year | First Author | Number | Age | Sex | History | Thyroid status | 1st CC | Examinations | Radiologic findings | Diagnosis | Treatment | Outcome |
|------|--------------|--------|-----|-----|---------|----------------|--------|--------------|---------------------|-----------|-----------|---------|
| 2010 | Bijlsma WR.  | 1      | 47  | F   | NR      | Autoimmune hypothyroidism | Progressive painless proptosis (OS) | NR | A posterior superior orbital mass (OS) | NSOI(4) | Oral prednisone | Complete resolution |
|      |              | 2      | 35  | F   | NR      | Primary hypothyroidism | Subacute eyelid swelling + proptosis + eyeball motility restriction + pain (OD) | NR | Lacrimal gland enlargement (OD) | NSOI | Methyl prednisolone IV | NR |
|      |              | 3      | 30  | M    | Diabetes mellitus + Crohn disease | Hyperthyroidism | Painless proptosis + eyelid motility restriction + upper eyelid retraction (OU) | NR | EON enlargement (OU) | GO | Radiotherapy + Oral prednisone | Complete resolution without therapy |
|      |              | 4      | 22  | M   | NR      | Euthyroidism | Proptosis + eyelid motility restriction + pain (OS) | NR | Medial superior orbital mass (OS) | NSOI | Oral prednisone | NR |
| 2011 | Kubota T.    | 5      | 64  | F   | NR      | GO associated with hyperthyroidism (Positive ATA) | Upper eyelid mass (OS) | NR | Anterior superior orbital infiltrative lesions (OU) | NSOI (IgG4-related Inflammation) | Oral prednisone | Partial resolution |
| 2012 | Tachibana S. | 6      | 52  | M   | Hyperuricemia Partial hepatectomy - Smoker | Hyperthyroid - Under treatment with Methimazol - Subclinical hypothyroidism at the time of complaint | Eye pain + Severe motility restriction (OS) + Diplopia | VA(20/20 (OD) 20/40 (IS) CAS(67) (OS) Postis + lid retraction (OS) Exophthalmometer: 17 mm (OD) + 17 mm (OS) | Simultaneous TED 12 and NSOI | Methyl prednisolone IV 1gr 3 times/ week | Dramatic improvement after 2 months: VA: 20/25 (OD) 20/22 (OS) CAS: 0/7 (OS) Exophthalmometer: 17 mm (OD) + 17 mm (OS) |
| 2014 | Detorakis E. | 7      | 46  | M    | Testicular seminoma surgically removed 20 years ago | Hyperthyroidism: (5 years) | Proptosis (OU) + Ocular hypertension (OD) | VA: 20/25 (OD) 20/20 (IS) IOP: 32 mmHg (OD) 17 mmHg (IS) Exophthalmometer: 26 mm (OD) + 26 mm (OS) | Fusiform EOM enlargement Specially in IR(13)(OD) + Infratemporal intraorbital tumor in apposition with the posterior aspect of the globe (OD) | Simultaneous TED and Sclerosing NSOI | Oral prednisone 1 mg/kg (6 weeks) | Reduction in size and vascularity after 6 months: IOP: 17 (OD) |
| 2015 | Shen T.      | 8      | 42  | M   | NR      | Hyperthyroidism (6 years) | Proptosis for 2 years + Moderate upper eyelid retraction + Moderate motility restriction (OD) | VA: 25/30 (OD) 25/20 (IS) IOP: normal (OU) Exophthalmometer: 24 mm (OD) + 17 mm (OS) | MR [15] + LR[16] enlargement with tendon sparing (OD) + Ambiguous soft tissue mass of 1.8 × 1.5 cm in retro bulbar cone region (OD) | Simultaneous TED and NSOI | Methyl prednisolone IV 500 mg (5 days) + oral prednisone 50 mg (5 days) + tapering during 2 months | Complete resolution No recurrence after 6 months: IOP: 17 (OD) |
|      |              | 9      | 49  | M   | NR      | Hyperthyroidism (8 years) - Under treatment with PTU | Proptosis for 8 years (OU) + Eye redness for 2 months (OU) + Mild diplopia for 2 months | VA : Normal (OU) Severe motility restriction (OU) Exophthalmometer: 27 mm (OD) + 26 mm (OS) | SR and IR enlargement with tendon sparing (OU) + Inferior orbital soft tissue mass of 2.1 × 1.4 cm (OD) + Inferior orbital soft tissue mass of 1.5 × 1.2 cm (OD) | Simultaneous TED and NSOI | Methyl prednisolone IV 500 mg (5 days) + oral prednisone 50 mg (5 days) + tapering during 1 months | Complete resolution |
|      |              | 10     | 48  | F   | NR      | Hyperthyroidism (5 years) | Proptosis (OU) | VA: Normal (OU) Orbital masses in lacrimal area (OU) + Inferior orbital mass (OS) Mild motility restriction in medial & lateral gaze (OS) + lateral gaze (OD) | LR & MR enlargement with tendon sparing (OS) Inferior orbital soft tissue mass of 1.5 × 1.2 cm (OS) MR enlargement (OD) 2 well-defined homogeneous soft tissue masses of 1.1 × 1.0 cm and | Simultaneous TED and NSOI | Docetaxel IV 10 mg (5days) + oral prednisone 40 mg (5 days) | Complete resolution |
| Year | Author & ID | Age | Gender | Chief complaint | Exophthalmometer | Simultaneous TED and NSOI (dacryoadenitis) | Endoscopic sinus drainage surgery & endoscopic medial orbital decompression (OD) & Oral prednisone | Partial resolution of proptosis |
|------|-------------|-----|--------|----------------|------------------|-------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------------------|
| 2017 | Shieh WS    | 68  | F      | Well controlled hypertension Smoker | 17 mm (OD) + 20 mm (OS) | Simultaneous TED and NSOI (dacryoadenitis) + Silent sinus syndrome | Endoscopic sinus drainage surgery & endoscopic medial orbital decompression (OD) & Oral prednisone | Partial resolution of proptosis |
|      |             |     |        |                | 0.9 x 0.6 cm in lacrimal gland areas (OU) | SR & R & MR enlargement with tendon sparing (OD) well circumscribed superior orbital mass (OD) lacrimal gland enlargement (OD) Maxillary sinus opacification & orbital floor bowing & bony erosion (OU) |                                                                                               |                                   |
|      |             |     |        |                |                  | Superior rectus muscle Inferior rectus muscle Medial rectus muscle Lateral rectus muscle |                                                                                                                                                   |                                   |

1- Chief complaint 2- Female 3- Not reported in the article 4- Nonspecific orbital inflammation 5- Extraocular muscles 6- Grave’s ophthalmopathy 7- Anti-thyroid antibodies 8- Male 9- Visual acuity 10- Clinical activity score 11- Superior rectus muscle 12- Thyroid eye disease 13- Inferior rectus muscle 14- Medial rectus muscle 15- Lateral rectus muscle
| Year | Outcome | Interval | 2nd CC | Examinations | Radiological findings | Diagnosis | Treatment | Outcome | Interval | 3rd CC | Examinations | Radiological findings | Diagnosis | Treatment | Outcome |
|------|---------|----------|--------|-------------|----------------------|-----------|-----------|---------|----------|--------|-------------|----------------------|-----------|-----------|---------|
| 2010 | Complete resolution | 11 months | NR | NR | Diffuse retro bulbar mass | NSOI (OD) | Oral prednisone | NR | 4 years | Eyelid retraction + proptosis (OD) | NR | EOM enlargement (OU) | GO (Positive ATA) | Surgical correction of eyelid retraction | Complete resolution |
| 2010 | NR | 4 months | Diplopia + Upper eyelid retraction (OS) | EOM enlargement (OS) | Unilateral GO (Positive ATA) | Radiotherapy | NR | 4 years | NR | EOM enlargement (OU) | GO (Positive ATA) | Methylprednisolone IV | NR |
| 2010 | Complete resolution without therapy | 9 years | Proptosis + eyelid motility restriction (OS) | Lacrimal gland enlargement (OS) | NSOI (Dacryoadenitis) | Oral prednisone | NR | 2 months | Proptosis + eyelid motility restriction (OC) | NR | Lacrimal gland enlargement (OD) | NSOI (Dacryoadenitis) | Oral prednisone | NR |
| 2010 | NR | 5 years | Progressive proptosis (OS) | EOM enlargement (OD) | GO (Positive ATA) (Normal TFT) | Surgical decompression | Complete resolution | - | - | - | - | - | - | - |
| 2011 | Partial resolution | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2012 | Dramatic improvement after 2 months: VA: 20/25 (OD) 20/22 (OS) CAS: 0/7 (OS) Exophthalmometer: 17 mm (OD) + 17 mm (OS) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2014 | Reduction in size and vascularity after 6 months IOP: 17 (OD) | - | - | - | - | - | - | - | - | - | - | - | - |
| 2015 | Complete resolution No recurrence after 6 months | - | - | - | - | - | - | - | - | - | - | - | - |
| 2017 | Partial resolution of proptosis | - | - | - | - | - | - | - | - | - | - | - | - | - |
imaging and even surgical biopsies if a mass is reported. Rheumatologic assessments appear to be mandatory in those with NSOI in the histopathological reports. Finally, TED and NSOI should be treated as independent diseases, however their pathophysiology and treatments may overlap.

Conclusions
Comorbidity of NSOI and TED, appearing either at the same time or at different periods, is really rare and occurs through unknown mechanisms. Ophthalmologists should be aware of this comorbidity and its influence on patient’s responses to conventional treatments. This comorbidity should be considered in poorly responsive or unresponsive patients. The correct diagnosis requires detailed history, accurate physical examination and appropriate diagnostic evaluations in such patients. Furthermore, more extensive studies with specific histopathological and molecular evaluations should be conducted to determine the mechanisms leading to NSOI and TED to discover whether their simultaneous occurrence reflects underlying connections or is merely coincidental.

Abbreviations
TED: Thyroid Eye Disease; CT-Scan: Computed Tomography Scan; MRI: Magnetic Resonance Imaging; NSOI: Non-Specific Orbital Inflammation; EOM: Extraocular Muscles; BCVA: Best Corrected Visual Acuity; RAPD: Relative Afferent Pupillary Defect; CAS: Clinical Activity Score; IOP: Intraocular Pressure; Anti-TPO: Anti-Thyroid Peroxidase

Acknowledgements
The authors would like to express their gratitude to the study patients for signing an informed consent which allowed us to publish their clinical information and imaging modalities.

Authors’ contributions
B.E. and M.F. contributed to the design of the study. B.E. M.F. A.D. and N.J. contributed to the data gathering. M.F. A.D. and N.J. contributed to the writing of the manuscript and B.E. and M.F. contributed to the revising of the manuscript. The author(s) read and approved the final manuscript.

Funding
No funding or financial support was received for the study.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
The research was conducted in full compliance with ethical principles and in accordance with the World Medical Association Declaration of Helsinki. The patients signed written informed consents for participation.

Consent for publication
The patients signed written informed consents for publication of their clinical information and photos.

Competing interest
The authors declare that they have no competing interests.

Author details
1Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran. 2Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Received: 18 January 2021 Accepted: 24 May 2021
Published online: 05 June 2021

References
1. Shan SJ, Douglas RS. The Pathophysiology of Thyroid Eye Disease. J Neuroophthalmol. 2014;34(2):177–85.
2. Barrio-Barrio J, Sabater AL, Bonet-Fariol E, Velázquez-Villoria Á, Galofré JC. Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. Journal of Ophthalmology. 2015;2015:249125.
3. McAlinden C. An overview of thyroid eye disease. Eye Vis (Lond). 2014 2014; 1.
4. Yerliṣtaş YS, Gündüz AK. Idiopathic Orbital Inflammation: Review of Literature and New Advances. Middle East Afr J Ophthalmol. 2018;25(2):71–80.
5. Bilımış WR, Kaliman R. Idiopathic Orbital Inflammation and Graves Ophthalmopathy. Arch Ophthalmol. 2010;128(1):131–2.
6. Detorakis ET, Haniotis V, Mavrikakis I, Drakonaki EE. Idiopathic sclerosing orbital inflammation and active Graves’ ophthalmopathy. Ophthalmic Plast Reconstr Surg. 2014;30(1):77–9.
7. Kubota T, Moritani S, Terasaki H. Ocular Adnexal IgG-Related Lymphoplasmacytic Infiltrative Disorder and Graves Ophthalmopathy. Arch Ophthalmol. 2011;129(9):805–20.
8. Shen T, Chen J, Lin J, Liu R, Yan J. Concomitant Idiopathic Orbital Inflammatory Pseudotumor and Thyroid-Associated Ophthalmopathy. J Craniofac Surg. 2015;26(6):e479-81.
9. Sheih WS, Huggins AB, Rabinowitz MR, Rosen MR, Rabinowitz MP. A case of concurrent silent sinus syndrome, thyroid eye disease, idiopathic orbital inflammatory syndrome, and dacryoadenitis. Orbit. 2017;36(6):462–4.
10. Tachibana S, Yokoi T, Sato S, Oda Y, Yanase T, Yamashita H. Idiopathic orbital myositis associated with Graves’ disease. Intern Med. 2013;52(7):787–90.
11. Eshraghi B, Sonboleetan SA, Abtahi M-A, Mirmohammadsadeghi A. Clinical characteristics, histopathology, and treatment outcomes in adult and pediatric patients with nonspecific orbital inflammation. Journal of Current Ophthalmology. 2019;33(3):327–34.
12. Lee MJ, Pland Ac, Choi Ac, Harrington CA, Wilson DJ, Dailey RA, et al. Non-specific orbital inflammation: Current understanding and unmet needs. Prog Retin Eye Res. 2020;100885.
13. Bagaglia SA, Meduri A, Inferrella L, Gennaro P, Gabriele G, Polito E, et al. Intraconal Retro-Orbital B-Type Antoni Neurinoma Causing Vision Loss. J Craniofac Surg. 2020;31(6):e597-e9.
14. Donato L, Scimone C, Abdalla EM, Nabil KM, D’Angelo R, et al. Possible A2E Mutagenic Effects on RPE Mitochondrial DNA from Innovative RNA-Seq Bioinformatics Pipeline. Antioxidants. 2020;9(11):1158.
15. Scimone C, Alibrandi S, Scalinci SZ, Trovato Battagliola E, D’Angelo R, et al. Expression of Pro-Angiogenic Markers Is Enhanced by Blue Light in Human RPE Cells. Antioxidants. 2020;9(1):1154.
16. Donato L, Scimone C, Alibrandi S, Abdalla EM, Nabil KM, D’Angelo R, et al. New Omics-Derived Perspectives on Retinal Dystrophies: Could Ion Channels-Encoding or Related Genes Act as Modifier of Pathological Phenotype? Int J Mol Sci. 2020;22(1).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.